DioMEDe Sciences has created a proprietary platform to create biological based drugs and cell therapies.  We are reducing the time to first-in-human testing from several years to months. Because of our Deep-Tech we are democratizing science and creating complete transparency across the industry. Our blockchain technology can provide regulatory bodies with direct access to all of our data in a secure and transparent manner. 

Our approach results in the true creation of the first cryptographic healthcare marketplace.  

Our solution is computationally aided drug design and deployment.  

• Combining Deep-Tech with the wet-laboratory, and translational research into the clinic will continue to drive efficiencies, cost savings, and reduce developmental bottlenecks; thus, creating more opportunities to cure disease and extend life. 
• Our approach is to expand our existing technologies for creating novel biologics & cell therapies that will provide lifesaving therapies at affordable prices. 
• We are expanding our approaches to the wetlab and clinic focusing curing rare pediatric cancers.
• These cures will have the largest impact on lifespan extension. Providing a 12 year old child with up to 7+ decades of life will be a remarkable achievement. 
• Within process development, we are creating tools to increase efficiencies in the manufacturing of cell therapies and critical supply chain management to create an end-to-end process from discovery to the patient bedside. 

While our pipeline is proprietary, it spans a series of novel targets focused on solid tumor biology within pediatric osteosarcomas (POS) that also play a role in pancreatic ductal adenocarcinoma (PDAC). A significant value is that our blockchain protected assets are real intellectual property (IP).

We are in discussions to deploy our technology with a global device company. This company is developing a bench side cell manufacturing device for on-demand personalized medicine. They also have a deep passion for POS and PDAC. This allows us to be one of the first to sample a tumor from a patient, screen for optimized biological characteristics, and begin treating the patient with custom designed living therapies to provide durable tumor erosion, remission and lifelong protection against the disease.